IntegraGen SA (ALINT.PA)

EUR 0.53

(0.0%)

Long Term Debt Summary of IntegraGen SA

  • IntegraGen SA's latest annual long term debt in 2023 was 642.28 Thousand EUR , down -42.86% from previous year.
  • IntegraGen SA's latest quarterly long term debt in 2024 Q2 was 869 Thousand EUR , down 0.0% from previous quarter.
  • IntegraGen SA reported annual long term debt of 1.12 Million EUR in 2022, down -31.15% from previous year.
  • IntegraGen SA reported annual long term debt of 1.63 Million EUR in 2021, down -16.4% from previous year.
  • IntegraGen SA reported quarterly long term debt of 831.13 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
  • IntegraGen SA reported quarterly long term debt of 642.28 Thousand EUR for 2023 FY, down -42.86% from previous quarter.

Annual Long Term Debt Chart of IntegraGen SA (2023 - 2008)

Historical Annual Long Term Debt of IntegraGen SA (2023 - 2008)

Year Long Term Debt Long Term Debt Growth
2023 642.28 Thousand EUR -42.86%
2022 1.12 Million EUR -31.15%
2021 1.63 Million EUR -16.4%
2020 1.95 Million EUR 710.27%
2019 241 Thousand EUR -58.26%
2018 577.44 Thousand EUR 6.95%
2017 539.94 Thousand EUR -63.82%
2016 1.49 Million EUR -6.28%
2015 1.59 Million EUR 42.18%
2014 1.12 Million EUR -32.33%
2013 1.65 Million EUR 894515.14%
2012 185.00 EUR -99.99%
2011 1.54 Million EUR 3545.97%
2010 42.37 Thousand EUR -52.99%
2009 90.13 Thousand EUR 39087.39%
2008 230.00 EUR 0.0%

Peer Long Term Debt Comparison of IntegraGen SA

Name Long Term Debt Long Term Debt Difference
ABIONYX Pharma SA 1.1 Million EUR 41.664%
ABIVAX Société Anonyme 44.69 Million EUR 98.563%
Adocia SA 4.54 Million EUR 85.853%
Aelis Farma SA 2.04 Million EUR 68.639%
Biophytis S.A. 3.11 Million EUR 79.355%
Advicenne S.A. 15.89 Million EUR 95.959%
genOway Société anonyme 5.51 Million EUR 88.363%
Medesis Pharma S.A. 1.2 Million EUR 46.477%
Neovacs S.A. 650 Thousand EUR 1.188%
NFL Biosciences SA 39.2 Thousand EUR -1538.344%
Plant Advanced Technologies SA 4.35 Million EUR 85.257%
Quantum Genomics Société Anonyme 1.96 Million EUR 67.236%
Sensorion SA 1.24 Million EUR 48.241%
Theranexus Société Anonyme 2.46 Million EUR 73.899%
TME Pharma N.V. - EUR -Infinity%
Valbiotis SA 3.89 Million EUR 83.523%
TheraVet SA 1 Million EUR 35.81%
Valerio Therapeutics Société anonyme 6.9 Million EUR 90.7%
argenx SE 15.35 Million EUR 95.817%
BioSenic S.A. 15.57 Million EUR 95.876%
Celyad Oncology SA 902 Thousand EUR 28.794%
DBV Technologies S.A. 4.52 Million USD 85.809%
Galapagos NV 4.94 Million EUR 87.009%
Genfit S.A. 62.25 Million EUR 98.968%
GeNeuro SA 6.49 Million EUR 90.107%
Hyloris Pharmaceuticals SA 344 Thousand EUR -86.709%
Innate Pharma S.A. 30.6 Million EUR 97.902%
Inventiva S.A. 25.61 Million EUR 97.493%
MaaT Pharma SA 5.42 Million EUR 88.161%
MedinCell S.A. 52.8 Million EUR 98.784%
Nanobiotix S.A. 41.66 Million EUR 98.458%
Onward Medical N.V. 16.3 Million EUR 96.061%
Oryzon Genomics S.A. 3.45 Million EUR 81.387%
OSE Immunotherapeutics SA 35.5 Million EUR 98.191%
Oxurion NV 117 Thousand EUR -448.957%
Pharming Group N.V. 123.65 Million EUR 99.481%
Poxel S.A. 40.14 Million EUR 98.4%
GenSight Biologics S.A. 1.04 Million EUR 38.714%
Transgene SA 17 Thousand EUR -3678.118%
Financière de Tubize SA - EUR -Infinity%
UCB SA 2.87 Billion EUR 99.978%
Valneva SE 132.76 Million EUR 99.516%
Vivoryon Therapeutics N.V. - EUR -Infinity%